Skip to main content
SpringerLink
Log in

Diseases frequently associated with epileptic seizures

  • Chapter
A Clinical Guide to Epileptic Syndromes and their Treatment

  • 2898 Accesses

Abstract

Any functional or structural cerebral derangement is a potential cause of epileptic seizures. Axis 4 of the ILAE Diagnostic Scheme (Table 1.1)1 is to specify the aetiology of epilepsies when known.1,2

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Engel J, Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: Report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42:796–803.

    Article  PubMed  Google Scholar 

  2. Engel J, Jr. Report of the ILAE classification core group. Epilepsia 2006;47:1558–1568.

    Article  PubMed  Google Scholar 

  3. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389–399.

    Article  Google Scholar 

  4. Myoclonus and epilepsy in childhood. Commission on Pediatric Epilepsy of the International League Against Epilepsy. Epilepsia 1997;38:1251–1254.

    Article  Google Scholar 

  5. Shibasaki H, Hallett M. Electrophysiological studies of myoclonus. Muscle Nerve 2005;31:157–174.

    Article  PubMed  Google Scholar 

  6. Berkovic SF, Andermann F, Carpenter S, Wolfe LS. Progressive myoclonus epilepsies: specific causes and diagnosis. N Engl J Med 1986;315:296–305.

    CAS  PubMed  Google Scholar 

  7. Classification of progressive myoclonus epilepsies and related disorders. Marseille Consensus Group. Ann Neurol 1990;28:113–116.

    Google Scholar 

  8. Delgado-Escueta AV, Ganesh S, Yamakawa K. Advances in the genetics of progressive myoclonus epilepsy. Am J Med Genet 2001;106:129–138.

    Article  CAS  PubMed  Google Scholar 

  9. Lehesjoki AE. Molecular background of progressive myoclonus epilepsy. EMBO J 2003;22:3473–3478.

    Article  CAS  PubMed  Google Scholar 

  10. Chan EM, Andrade DM, Franceschetti S, Minassian B. Progressive myoclonus epilepsies: EPM1, EPM2A, EPM2B. Adv Neurol 2005;95:47–57.

    PubMed  Google Scholar 

  11. Genton P, Malafosse A, Moulard B, Rogel-Ortiz FJ, Dravet C, Bureau M, et al. Progressive myoclonus epilepsies. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence. Fourth edition, pp 441–465. Montrouge, France: John Libbey Eurotext; 2005.

    Google Scholar 

  12. Wolf NI, Rahman S, Schmitt B, Taanman JW, Duncan AJ, Harting I, et al. Status epilepticus in children with Alpers’ disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009;50:1596–1607.

    Article  PubMed  Google Scholar 

  13. Tzoulis C, Engelsen BA, Telstad W, Aasly J, Zeviani M, Winterthun S, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain 2006;129 Pt 7:1685–1692.

    Article  PubMed  Google Scholar 

  14. Galliciotti G, Sonderegger P. Neuroserpin. Front Biosci 2006;11:33–45.

    Article  CAS  PubMed  Google Scholar 

  15. Park JK, Orvisky E, Tayebi N, Kaneski C, Lamarca ME, Stubblefield BK, et al. Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatr Res 2003;53:387–395.

    Article  PubMed  Google Scholar 

  16. Pastores GM, Hughes DA. Gaucher disease. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=gaucher. Last accessed August 2009.

    Google Scholar 

  17. Badhwar A, Berkovic SF, Dowling JP, Gonzales M, Narayanan S, Brodtmann A, et al. Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain 2004;127 Pt 10:2173–2182.

    Article  PubMed  Google Scholar 

  18. Berkovic SF. Progresssive myoclonus epilepsies. In: Engel J Jr, Pedley TA, eds. Philadelphia: Lippincott Williams & Wilkins, A Wolters Kluwer Business, 2008:2525–2535.

    Google Scholar 

  19. Rho JM. Basic science behind the catastrophic epilepsies. Epilepsia 2004;45Suppl 5:5–11.

    Article  PubMed  Google Scholar 

  20. Lalioti MD, Mirotsou M, Buresi C, Peitsch MC, Rossier C, Ouazzani R, et al. Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). Am J Hum Genet 1997;60:342–351.

    CAS  PubMed  Google Scholar 

  21. Kalviainen R, Khyuppenen J, Koskenkorva P, Eriksson K, Vanninen R, Mervaala E. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008;49:549–556.

    Article  CAS  PubMed  Google Scholar 

  22. Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia 2006;47:860–866.

    Article  PubMed  Google Scholar 

  23. Lehesjoki AE, Kalviainen R. Unverricht-Lundborg disease. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=epm1. Last accessed August 2009.

    Google Scholar 

  24. Lundborg H. Race, cultural groups social differentiation: Race biological perspectives. Social Forces 1931;9:397–401.

    Article  Google Scholar 

  25. Koskiniemi M. Psychological findings in progressive myoclonus epilepsy without Lafora bodies. Epilepsia 1974;15:537–545.

    Article  CAS  PubMed  Google Scholar 

  26. Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996;271:1731–1734.

    Article  CAS  PubMed  Google Scholar 

  27. Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ. “Baltic” myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 1983;2:838–842.

    Article  CAS  PubMed  Google Scholar 

  28. Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004;45:678–681.

    Article  CAS  PubMed  Google Scholar 

  29. Kinrions P, Ibrahim N, Murphy K, Lehesjoki AE, Jarvela I, Delanty N. Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy. Neurology 2003;60:1394–1395.

    Article  CAS  PubMed  Google Scholar 

  30. Hurd RW, Wilder BJ, Helveston WR, Uthman BM. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology 1996;47:1264–1268.

    CAS  PubMed  Google Scholar 

  31. Smith B, Shatz R, Elisevich K, Bespalova IN, Burmeister M. Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia 2000;41:1046–1048.

    Article  CAS  PubMed  Google Scholar 

  32. Genton P, Guerrini R. Antimyoclonic effects of alcohol in progressive myoclonus epilepsy. Neurology 1990;40:1412–1416.

    CAS  PubMed  Google Scholar 

  33. Yokota T, Kagamihara Y, Hayashi H, Tsukagoshi H, Tanabe H. Nicotine-sensitive paresis. Neurology 1992;42:382–388.

    CAS  PubMed  Google Scholar 

  34. Minassian BA. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease. Adv Neurol 2002;89:199–210.

    PubMed  Google Scholar 

  35. Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat 2009;30:715–723.

    Article  CAS  PubMed  Google Scholar 

  36. Delgado-Escueta AV. Advances in lafora progressive myoclonus epilepsy. Curr Neurol Neurosci Rep 2007;7:428–433.

    Article  CAS  PubMed  Google Scholar 

  37. Gomez-Abad C, Gomez-Garre P, Gutierrez-Delicado E, Saygi S, Michelucci R, Tassinari CA, et al. Lafora disease due to EPM2B mutations: a clinical and genetic study. Neurology 2005;64:982–986.

    CAS  PubMed  Google Scholar 

  38. Franceschetti S, Gambardella A, Canafoglia L, Striano P, Lohi H, Gennaro E, et al. Clinical and genetic findings in 26 Italian patients with Lafora disease. Epilepsia 2006;47:640–643.

    Article  PubMed  Google Scholar 

  39. Andrade DM, Ackerley CA, Minett TS, Teive HA, Bohlega S, Scherer SW, et al. Skin biopsy in Lafora disease: genotype-phenotype correlations and diagnostic pitfalls. Neurology 2003;61:1611–1614.

    CAS  PubMed  Google Scholar 

  40. Kumada S, Kubota M, Hayashi M, Uchiyama A, Kurata K, Kagamihara Y. Fixation-sensitive myoclonus in Lafora disease. Neurology 2006;66:1574–1576.

    Article  CAS  PubMed  Google Scholar 

  41. Pichiecchio A, Veggiotti P, Cardinali S, Longaretti F, Poloni GU, Uggetti C. Lafora disease: Spectroscopy study correlated with neuropsychological findings. Eur J Paediatr Neurol 2008;12:342–347.

    Article  PubMed  Google Scholar 

  42. Mole SE, Williams RE, Goebel HH. Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 2005;6:107–126.

    Article  PubMed  Google Scholar 

  43. Mole SE. The genetic spectrum of human neuronal ceroid-lipofuscinoses. Brain Pathol 2004;14:70–76.

    Article  CAS  PubMed  Google Scholar 

  44. Haltia M. The neuronal ceroid-lipofuscinoses. J Neuropathol Exp Neurol 2003;62:1–13.

    PubMed  Google Scholar 

  45. Gardiner RM. Clinical features and molecular genetic basis of the neuronal ceroid lipofuscinoses. Adv Neurol 2002;89:211–215.

    PubMed  Google Scholar 

  46. Palmer DN, Oswald MJ, Westlake VJ, Kay GW. The origin of fluorescence in the neuronal ceroid lipofuscinoses (Batten disease) and neuron cultures from affected sheep for studies of neurodegeneration. Arch Gerontol Geriatr 2002;34:343–357.

    Article  CAS  PubMed  Google Scholar 

  47. Weimer JM, Kriscenski-Perry E, Elshatory Y, Pearce DA. The neuronal ceroid lipofuscinoses: mutations in different proteins result in similar disease. Neuromolecular Med 2002;1:111–124.

    Article  CAS  PubMed  Google Scholar 

  48. Lohi H, Chan EM, Scherer SW, Minassian BA. On the road to tractability: the current biochemical understanding of progressive myoclonus epilepsies. Adv Neurol 2006;97:399–415.

    PubMed  Google Scholar 

  49. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005;4:239–248.

    Article  CAS  PubMed  Google Scholar 

  50. Zupanc ML, Legros B. Progressive myoclonic epilepsy. Cerebellum 2004;3:156–171.

    Article  PubMed  Google Scholar 

  51. Uvebrant P, Hagberg B. Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures. Neuropediatrics 1997;28:6–8.

    Article  CAS  PubMed  Google Scholar 

  52. Cardona F, Rosati E. Neuronal ceroid-lipofuscinoses in Italy: an epidemiological study. Am J Med Genet 1995;57:142–143.

    Article  CAS  PubMed  Google Scholar 

  53. Weleber RG, Gupta N, Trzupek KM, Wepner MS, Kurz DE, Milam AH. Electroretinographic and clinicopathologic correlations of retinal dysfunction in infantile neuronal ceroid lipofuscinosis (infantile Batten disease). Mol Genet Metab 2004;83:128–137.

    Article  CAS  PubMed  Google Scholar 

  54. Caraballo R, Sologuestua A, Ruggieri VL, Monges S, Cersosimo R, Taratuto AL, et al. [Clinical and electroencephalographic aspects of late infantile neuronal ceroid lipofuscinosis.] Rev Neurol 2005;40:135–140.

    CAS  PubMed  Google Scholar 

  55. Hirvasniemi A, Lang H, Lehesjoki AE, Leisti J. Northern epilepsy syndrome: an inherited childhood onset epilepsy with associated mental deterioration. J Med Genet 1994;31:177–182.

    Article  CAS  PubMed  Google Scholar 

  56. Spranger J, Cantz M. Mucolipidosis I, the cherry red-spot-myoclonus syndrome and neuraminidase deficiency. Birth Defects Orig Artic Ser 1978;14:105–112.

    CAS  PubMed  Google Scholar 

  57. Lowden JA, O’Brien JS. Sialidosis: a review of human neuraminidase deficiency. Am J Hum Genet 1979;31:1–18.

    CAS  PubMed  Google Scholar 

  58. Federico A, Battistini S, Ciacci G, De Stefano N, Gatti R, Durand P, et al. Cherry-red spot myoclonus syndrome (type I sialidosis). Dev Neurosci 1991;13:320–326.

    Article  CAS  PubMed  Google Scholar 

  59. Buccoliero R, Palmeri S, Federico A. Ataxia, myoclonus and macular degeneration. www.orpha.net/data/patho/GB/uk-ataxiamyoclonus.pdf, 2003. Last accessed August 2009.

    Google Scholar 

  60. Rapin I, Goldfischer S, Katzman R, Engel J, Jr, O’Brien JS. The cherryred spot—myoclonus syndrome. Ann Neurol 1978;3:234–242.

    Article  CAS  PubMed  Google Scholar 

  61. Till JS, Roach ES, Burton BK. Sialidosis (neuraminidase deficiency) types I and II: neuro-ophthalmic manifestations. J Clin Neuroophthalmol 1987;7:40–44.

    CAS  PubMed  Google Scholar 

  62. Palmeri S, Villanova M, Malandrini A, van Diggelen OP, Huijmans JG, Ceuterick C, et al. Type I sialidosis: a clinical, biochemical and neuroradiological study. Eur Neurol 2000;43:88–94.

    Article  CAS  PubMed  Google Scholar 

  63. Caciotti A, Di RM, Filocamo M, Grossi S, Traverso F, d’Azzo A, et al. Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients. J Neurol 2009;256:1911–1915.

    Article  CAS  PubMed  Google Scholar 

  64. Oheda Y, Kotani M, Murata M, Sakuraba H, Kadota Y, Tatano Y, et al. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement. Glycobiology 2006;16:271–280.

    Article  CAS  PubMed  Google Scholar 

  65. Di Mauro S, Hirano M. MERRF [myoclonic epilepsy associated with ragged-red fibers]. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=merrf. Last accessed August 2009.

    Google Scholar 

  66. Hirano M, Kunz WS, DiMauro S. Mitochondrial diseases. In: Engel J Jr, Pedley TA, eds. Epilepsy: a comprehensive textbook, second edition. pp 2621–2630. Philladelphia: Lippincott William and Wilkins, 2008.

    Google Scholar 

  67. Fukuhara N. Clinicopathological features of MERRF. Muscle Nerve 1995;3:S90–S94.

    Article  CAS  PubMed  Google Scholar 

  68. Berkovic SF, Carpenter S, Evans A, Karpati G, Shoubridge EA, Andermann F, et al. Myoclonus epilepsy and ragged-red fibres (MERRF). 1. A clinical, pathological, biochemical, magnetic resonance spectrographic and positron emission tomographic study. Brain 1989;112 Pt 5:1231–1260.

    Article  PubMed  Google Scholar 

  69. Mancuso M, Galli R, Pizzanelli C, Filosto M, Siciliano G, Murri L. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006;243:97–99.

    Article  CAS  PubMed  Google Scholar 

  70. Crest C, Dupont S, LeGuern E, Adam C, Baulac M. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004;62:640–643.

    CAS  PubMed  Google Scholar 

  71. Taivassalo T, Haller RG. Exercise and training in mitochondrial myopathies. Med Sci Sports Exerc 2005;37:2094–2101.

    Article  CAS  PubMed  Google Scholar 

  72. Tsuji S. Dentatorubral-pallidoluysian atrophy (DPRLA). http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=drpla. Last accessed August 2009.

    Google Scholar 

  73. Hattori M, Yuasa H, Takada K, Yamada T, Yamada K, Kamimoto K, et al. Genetic analysis of a dentatorubral-pallidoluysian atrophy family: relevance to apparent sporadic cases. Intern Med 1999;38:287–289.

    Article  CAS  PubMed  Google Scholar 

  74. Licht DJ, Lynch DR. Juvenile dentatorubral-pallidoluysian atrophy: new clinical features. Pediatr Neurol 2002;26:51–54.

    Article  PubMed  Google Scholar 

  75. Watarai M, Hashimoto T, Yamamoto K, Matsumoto Y, Tada T, Ikeda S. Pallidotomy for severe generalized chorea of juvenile-onset dentatorubral-pallidoluysian atrophy. Neurology 2003;61:1452–1454.

    CAS  PubMed  Google Scholar 

  76. Wardle M, Morris HR, Robertson NP. Clinical and genetic characteristics of non-Asian dentatorubral-pallidoluysian atrophy: A systematic review. Mov Disord 2009;24:1636–1640.

    Article  PubMed  Google Scholar 

  77. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994;6:9–13.

    Article  CAS  PubMed  Google Scholar 

  78. Burke JR, Ikeuchi T, Koide R, Tsuji S, Yamada M, Pericak-Vance MA, et al. Dentatorubral-pallidoluysian atrophy and Haw River syndrome. Lancet 1994;344:1711–1712.

    Article  CAS  PubMed  Google Scholar 

  79. Ikeuchi T, Koide R, Tanaka H, Onodera O, Igarashi S, Takahashi H, et al. Dentatorubral-pallidoluysian atrophy: clinical features are closely related to unstable expansions of trinucleotide (CAG) repeat. Ann Neurol 1995;37:769–775.

    Article  CAS  PubMed  Google Scholar 

  80. Naito H, Oyanagi S. Familial myoclonus epilepsy and choreoathetosis: hereditary dentatorubral-pallidoluysian atrophy. Neurology 1982;32:798–807.

    CAS  PubMed  Google Scholar 

  81. Adachi N, Arima K, Asada T, Kato M, Minami N, Goto Y, et al. Dentatorubral-pallidoluysian atrophy (DRPLA) presenting with psychosis. J Neuropsychiatry Clin Neurosci 2001;13:258–260.

    CAS  PubMed  Google Scholar 

  82. Koide R, Onodera O, Ikeuchi T, Kondo R, Tanaka H, Tokiguchi S, et al. Atrophy of the cerebellum and brainstem in dentatorubral pallidoluysian atrophy. Influence of CAG repeat size on MRI findings. Neurology 1997;49:1605–1612.

    CAS  PubMed  Google Scholar 

  83. Egawa K, Takahashi Y, Kubota Y, Kubota H, Inoue Y, Fujiwara T, et al. Electroclinical features of epilepsy in patients with juvenile type dentatorubral-pallidoluysian atrophy. Epilepsia 2008;49:2041–2049.

    Article  PubMed  Google Scholar 

  84. Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA, et al. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A 2006;140:413–418.

    PubMed  Google Scholar 

  85. Williams CA, Dagli AI, Driscoll DJ. Angelman syndrome. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=angelman. Last accessed August 2009.

    Google Scholar 

  86. Valente KD, Koiffmann CP, Fridman C, Varella M, Kok F, Andrade JQ, et al. Epilepsy in patients with angelman syndrome caused by deletion of the chromosome 15q11–13. Arch Neurol 2006;63:122–128.

    Article  PubMed  Google Scholar 

  87. Galvan-Manso M, Campistol J, Conill J, Sanmarti FX. Analysis of the characteristics of epilepsy in 37 patients with the molecular diagnosis of Angelman syndrome. Epileptic Disord 2005;7:19–25.

    PubMed  Google Scholar 

  88. Guerrini R, Carrozzo R, Rinaldi R, Bonanni P. Angelman syndrome: etiology, clinical features, diagnosis, and management of symptoms. Paediatr Drugs 2003;5:647–661.

    Article  PubMed  Google Scholar 

  89. Handforth A, DeLorey TM, Homanics GE, Olsen RW. Pharmacologic evidence for abnormal thalamocortical functioning in GABA receptor beta3 subunit-deficient mice, a model of Angelman syndrome. Epilepsia 2005;46:1860–1870.

    Article  CAS  PubMed  Google Scholar 

  90. Stecker MM, Myers SM. Reserpine responsive myoclonus and hyperpyrexia in a patient with Angelman syndrome. Clin Neurol Neurosurg 2003;105:183–187.

    Article  PubMed  Google Scholar 

  91. Angelman H. Puppet children. A report on three cases. Dev Med Child Neurol 1965;7:681–688.

    Article  Google Scholar 

  92. Laan LA, Renier WO, Arts WF, Buntinx IM, vd B, I, Stroink H, et al. Evolution of epilepsy and EEG findings in Angelman syndrome. Epilepsia 1997;38:195–199.

    Article  CAS  PubMed  Google Scholar 

  93. Guerrini R, De Lorey TM, Bonanni P, Moncla A, Dravet C, Suisse G, et al. Cortical myoclonus in Angelman syndrome. Ann Neurol 1996;40:39–48.

    Article  CAS  PubMed  Google Scholar 

  94. Viani F, Romeo A, Viri M, Mastrangelo M, Lalatta F, Selicorni A, et al. Seizure and EEG patterns in Angelman’s syndrome. J Child Neurol 1995;10:467–471.

    Article  CAS  PubMed  Google Scholar 

  95. Dalla BB, Fontana E, Darra F. Myoclonic status in nonprogressive encephalopathies. Adv Neurol 2005;95:59–70.

    Google Scholar 

  96. Jiang Y, Lev-Lehman E, Bressler J, Tsai TF, Beaudet AL. Genetics of Angelman syndrome. Am J Hum Genet 1999;65:1–6.

    Article  CAS  PubMed  Google Scholar 

  97. Boyes L, Wallace AJ, Krajewska-Walasek M, Chrzanowska KH, Clayton-Smith J, Ramsden S. Detection of a deletion of exons 8–16 of the UBE3A gene in familial Angelman syndrome using a semi-quantitative dosage PCR based assay. Eur J Med Genet 2006;49:472–480.

    Article  CAS  PubMed  Google Scholar 

  98. Johnstone KA, DuBose AJ, Futtner CR, Elmore MD, Brannan CI, Resnick JL. A human imprinting centre demonstrates conserved acquisition but diverged maintenance of imprinting in a mouse model for Angelman syndrome imprinting defects. Hum Mol Genet 2006;15:393–404.

    Article  CAS  PubMed  Google Scholar 

  99. Procter M, Chou LS, Tang W, Jama M, Mao R. Molecular diagnosis of Prader-Willi and Angelman syndromes by methylation-specific melting analysis and methylation-specific multiplex ligation-dependent probe amplification. Clin Chem 2006;52:1276–1283.

    Article  CAS  PubMed  Google Scholar 

  100. White HE, Durston VJ, Harvey JF, Cross NC. Quantitative analysis of SNRPN (correction of SRNPN) gene methylation by pyrosequencing as a diagnostic test for Prader-Willi syndrome and Angelman syndrome. Clin Chem 2006;52:1005–1013.

    Article  CAS  PubMed  Google Scholar 

  101. Williams C. Angelman syndrome scientific symposium on the structure and function of UBE3A/E6AP. J Child Neurol 2009;24:904–908.

    Article  PubMed  Google Scholar 

  102. Boyd SG, Harden A, Patton MA. The EEG in early diagnosis of the Angelman (happy puppet) syndrome. Eur J Pediatr 1988;147:508–513.

    Article  CAS  PubMed  Google Scholar 

  103. Laan LA, Vein AA. Angelman syndrome: is there a characteristic EEG? Brain Dev 2005;27:80–87.

    Article  PubMed  Google Scholar 

  104. Huber B, Seidel M. Update on treatment of epilepsy in people with intellectual disabilities. Curr Opin Psychiatry 2006;19:492–496.

    Article  PubMed  Google Scholar 

  105. Pranzatelli MR. Myoclonus in childhood. Semin Pediatr Neurol 2003;10:41–51.

    Article  PubMed  Google Scholar 

  106. Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 2003;44Suppl 11:27–37.

    Article  CAS  PubMed  Google Scholar 

  107. Pellock JM. Myoclonic epilepsies: syndromes and their treatment. Suppl Clin Neurophysiol 2004;57:425–432.

    Article  PubMed  Google Scholar 

  108. Medina MT, Martinez-Juarez IE, Duron RM, Genton P, Guerrini R, Dravet C, et al. Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood. Adv Neurol 2005;95:307–323.

    PubMed  Google Scholar 

  109. Sankar R, Wheless JW, Dravet C, Guerrini R, Medina MT, Bureau M, et al. Treatment of myoclonic epilepsies in infancy and early childhood. Adv Neurol 2005;95:289–298.

    PubMed  Google Scholar 

  110. Panayiotopoulos CP. The epilepsies: seizures, syndromes and management. Oxford: Bladon Medical Publishing; 2005.

    Google Scholar 

  111. Frucht S, Murray CR, Lefler BJ. Myoclonus. www.wemove.org/myo/, 2004. Last accessed May 2006.

    Google Scholar 

  112. Valeta T. Parental needs of children with epileptic seizures and management issues. In: Panayiotopoulos CP, ed. Volume 1: A practical quide to childhood epilepsies, pp 196–201. Oxford: Medicinae, 2006.

    Google Scholar 

  113. Pranzatelli MR, Tate ED. Chloral hydrate for progressive myoclonus epilepsy: a new look at an old drug. Pediatr Neurol 2001;25:385–389.

    Article  CAS  PubMed  Google Scholar 

  114. Fejerman N, Caraballo R, Cersosimo R. Ketogenic diet in patients with Dravet syndrome and myoclonic epilepsies in infancy and early childhood. Adv Neurol 2005;95:299–305.

    PubMed  Google Scholar 

  115. Panayiotopoulos CP. Main antimyoclonic antiepileptic drugs. In: Panayiotopoulos CP, ed. Volume 2: Idiopathic generalised epilepsieswith myoclonic jerks, pp 180–188. Oxford: Medicinae, 2007.

    Google Scholar 

  116. Shorvon S, Perucca E, Engel J Jr, eds. The treatment of epilepsy, third edition, pp 1–1056. Oxford: Wiley-Blackwell, 2009.

    Google Scholar 

  117. Hitiris N, Brodie MJ. Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs. Epilepsia 2005;46Suppl 9:149–153.

    Article  CAS  PubMed  Google Scholar 

  118. Oguni H, Uehara T, Tanaka T, Sunahara M, Hara M, Osawa M. Dramatic effect of ethosuximide on epileptic negative myoclonus: implications for the neurophysiological mechanism. Neuropediatrics 1998;29:29–34.

    Article  CAS  PubMed  Google Scholar 

  119. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998;29:147–154.

    Article  CAS  PubMed  Google Scholar 

  120. Shorvon SD. Piracetam. In: Shorvon S, Perucca E, Engel J Jr, eds. The treatment of epilepsy, third edition, pp 619–625 Oxford: Willey-Blackwell, 2009.

    Google Scholar 

  121. Obeso JA, Artieda J, Quinn N, Rothwell JC, Luquin MR, Vaamonde J, et al. Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988;11:529–536.

    Article  CAS  PubMed  Google Scholar 

  122. Koskiniemi M, Van Vleymen B, Hakamies L, Lamusuo S, Taalas J. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998;64:344–348.

    Article  CAS  PubMed  Google Scholar 

  123. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000;2:99–105.

    CAS  PubMed  Google Scholar 

  124. Fedi M, Reutens D, Dubeau F, Andermann E, D’Agostino D, Andermann F. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001;58:781–786.

    Article  CAS  PubMed  Google Scholar 

  125. Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006;15:214–248.

    Article  PubMed  Google Scholar 

  126. Grunewald R. Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia 2005;46Suppl 9:154–160.

    Article  CAS  PubMed  Google Scholar 

  127. Striano P, Manganelli F, Boccella P, Perretti A, Striano S. Levetiracetam in patients with cortical myoclonus: A clinical and electrophysiological study. Mov Disord 2005;20:1610–1614.

    Article  PubMed  Google Scholar 

  128. Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, Mancardi MM, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007;69:250–254.

    Article  CAS  PubMed  Google Scholar 

  129. Patsalos PN. Levetiracetam. Rev Contemp Pharmacother 2004;13:1–168.

    CAS  Google Scholar 

  130. Glauser TA. Levetiracetam in childhood epilepsies. In: Panayiotopoulos CP, ed. Volume 1: A practical guide to childhood epilepsies, pp 168–178. Oxford: Medicinae, 2006.

    Google Scholar 

  131. Agarwal P, Frucht SJ. Myoclonus. Curr Opin Neurol 2003;16:515–521.

    Article  PubMed  Google Scholar 

  132. Van Zandijcke M. Treatment of myoclonus. Acta Neurol Belg 2003;103:66–70.

    PubMed  Google Scholar 

  133. Genton P, Gelisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000;2:209–212.

    CAS  PubMed  Google Scholar 

  134. Gelisse P, Crespel A, Genton P, Baldy-Moulinier M. Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 2003;107:302–303.

    Article  CAS  PubMed  Google Scholar 

  135. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57:1112–1114.

    CAS  PubMed  Google Scholar 

  136. Krauss GL, Bergin A, Kramer RE, Cho YW, Reich SG. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001;56:411–412.

    CAS  PubMed  Google Scholar 

  137. Schauer R, Singer M, Saltuari L, Kofler M. Suppression of cortical myoclonus by levetiracetam. Mov Disord 2002;17:411–415.

    Article  PubMed  Google Scholar 

  138. Kasteleijn-Nolst Trenite DG, Hirsch E. Levetiracetam: preliminary efficacy in generalized seizures. Epileptic Disord 2003;5Suppl 1:S39–S44.

    PubMed  Google Scholar 

  139. Covanis A, Stodieck SR, Wilkins AJ. Treatment of photosensitivity. Epilepsia 2004;45Suppl 1:40–45.

    Article  PubMed  Google Scholar 

  140. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607–616.

    Article  CAS  PubMed  Google Scholar 

  141. Prasad A, Knowlton RC, Mendez M, Martin R, Kuzniecky R, Faught E. A comparison of lamotrigine and topiramate in juvenile myoclonic epilepsy. Epilepsia 2002;43Suppl 7:198–199.

    Google Scholar 

  142. Prasad A, Kuzniecky RI, Knowlton RC, Welty TE, Martin RC, Mendez M, et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003;60:1100–1105.

    Article  PubMed  Google Scholar 

  143. Bergey GK. Evidence-based treatment of idiopathic generalized epilepsies with new antiepileptic drugs. Epilepsia 2005;46Suppl 9:161–168.

    Article  CAS  PubMed  Google Scholar 

  144. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003;107:165–175.

    Article  CAS  PubMed  Google Scholar 

  145. Wheless JW, Neto W, Wang S. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol 2004;19:135–141.

    PubMed  Google Scholar 

  146. Cross JH. Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure 2002;11:406–410.

    Article  PubMed  Google Scholar 

  147. Aykutlu E, Baykan B, Gurses C, Bebek N, Buyukbabani N, Gokyigit A. Add-on therapy with topiramate in progressive myoclonic epilepsy. Epilepsy Behav 2005;6:260–263.

    Article  PubMed  Google Scholar 

  148. Ceulemans B, Boel M, Claes L, Dom L, Willekens H, Thiry P, et al. Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol 2004;19:516–521.

    Article  PubMed  Google Scholar 

  149. Siniscalchi A, Mancuso F, Russo E, Ibbadu GF, De Sarro G. Spinal myoclonus responsive to topiramate. Mov Disord 2004;19:1380–1381.

    Article  PubMed  Google Scholar 

  150. Conry JA. Pharmacologic treatment of the catastrophic epilepsies. Epilepsia 2004;45Suppl 5:12–16.

    Article  CAS  PubMed  Google Scholar 

  151. Aldenkamp AP, Baker G, Mulder OG, Chadwick D, Cooper P, Doelman J, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41:1167–1178.

    Article  CAS  PubMed  Google Scholar 

  152. Kockelmann E, Elger CE, Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 2003;54:171–178.

    Article  CAS  PubMed  Google Scholar 

  153. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003;2:473–481.

    Article  CAS  PubMed  Google Scholar 

  154. Willmore LJ (ed). International experiences and perspectives: zonisamide. Seizure 2004;13Suppl 1:S1–S72.

    Google Scholar 

  155. Kothare SV, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004;6:267–270.

    PubMed  Google Scholar 

  156. Szaflarski JP. Effects of zonisamide on the electroencephalogram of a patient with juvenile myoclonic epilepsy. Epilepsy Behav 2004;5:1024–1026.

    Article  PubMed  Google Scholar 

  157. Kagitani-Shimono K, Imai K, Okamoto N, Ono J, Okada S. Unverricht-Lundborg disease with cystatin B gene abnormalities. Pediatr Neurol 2002;26:55–60.

    Article  PubMed  Google Scholar 

  158. Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today (Barc) 2005;41:589–597.

    Article  CAS  Google Scholar 

  159. Kyllerman M, Ben Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998;29:109–114.

    Article  CAS  PubMed  Google Scholar 

  160. Vossler DG, Conry JA, Murphy JV. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 2008;10:31–34.

    PubMed  Google Scholar 

  161. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508–512.

    Article  CAS  PubMed  Google Scholar 

  162. Guerrini R, Belmonte A, Parmeggiani L, Perucca E. Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev 1999;21:420–424.

    Article  CAS  PubMed  Google Scholar 

  163. Janszky J, Rasonyi G, Halasz P, Olajos S, Perenyi J, Szucs A, et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level-report of two cases. Clin Neuropharmacol 2000;23:86–89.

    Article  CAS  PubMed  Google Scholar 

  164. Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000;55:1758.

    CAS  PubMed  Google Scholar 

  165. Carrazana EJ, Wheeler SD. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2001;56:1424–1425.

    CAS  PubMed  Google Scholar 

  166. Cerminara C, Montanaro ML, Curatolo P, Seri S. Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy. Neurology 2004;63:373–375.

    CAS  PubMed  Google Scholar 

  167. Crespel A, Genton P, Berramdane M, Coubes P, Monicard C, Baldy-Moulinier M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005;65:762–764.

    Article  CAS  PubMed  Google Scholar 

  168. Rosenhagen MC, Schmidt U, Weber F, Steiger A. Combination therapy of lamotrigine and escitalopram may cause myoclonus. J Clin Psychopharmacol 2006;26:346–347.

    Article  PubMed  Google Scholar 

  169. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1–43.

    Article  PubMed  Google Scholar 

  170. Malawska B, Kulig K. Brivaracetam: a new drug in development for epilepsy and neuropathic pain. Expert Opin Investig Drugs 2008;17:361–369.

    Article  CAS  PubMed  Google Scholar 

  171. Obeso JA, Rothwell JC, Quinn NP, Lang AE, Thompson C, Marsden CD. Cortical reflex myoclonus responds to intravenous lisuride. Clin Neuropharmacol 1983;6:231–240.

    Article  CAS  PubMed  Google Scholar 

  172. Obeso JA, Rothwell JC, Quinn NP, Lang AE, Artieda J, Marsden CD. Lisuride in the treatment of myoclonus. Adv Neurol 1986;43:191–196.

    CAS  PubMed  Google Scholar 

  173. Arnold GL, Griebel ML, Valentine JL, Koroma DM, Kearns GL. Dextromethorphan in nonketotic hyperglycinaemia: metabolic variation confounds the dose-response relationship. J Inherit Metab Dis 1997;20:28–38.

    Article  CAS  PubMed  Google Scholar 

  174. Chien YH, Hsu CC, Huang A, Chou SP, Lu FL, Lee WT, et al. Poor outcome for neonatal-type nonketotic hyperglycinemia treated with high-dose sodium benzoate and dextromethorphan. J Child Neurol 2004;19:39–42.

    Article  PubMed  Google Scholar 

  175. Jan JE, Connolly MB, Hamilton D, Freeman RD, Laudon M. Melatonin treatment of non-epileptic myoclonus in children. Dev Med Child Neurol 1999;41:255–259.

    Article  CAS  PubMed  Google Scholar 

  176. Molina-Carballo A, Munoz-Hoyos A, Reiter RJ, Sanchez-Forte M, Moreno-Madrid F, Rufo-Campos M, et al. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years’ experience. J Pineal Res 1997;23:97–105

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. C P Panayiotopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Healthcare Ltd

About this chapter

Cite this chapter

Panayiotopoulos, C.P. (2010). Diseases frequently associated with epileptic seizures. In: A Clinical Guide to Epileptic Syndromes and their Treatment. Springer, London. https://doi.org/10.1007/978-1-84628-644-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-644-5_17

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-643-8

  • Online ISBN: 978-1-84628-644-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation